Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Drug Naming Pilot Moves Forward, But Industry May Need Sweeter Rewards

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms lack explicit incentives to participate in the proposed self-evaluation, which will be discussed at a public meeting June 5-6.

You may also be interested in...



Trade Name “Bank” Proposed For Neutral/Extreme Controls In FDA Pilot

FDA’s proposal includes limited number of control names.

Trade Name “Bank” Proposed For Neutral/Extreme Controls In FDA Pilot

FDA’s proposal includes limited number of control names.

FDA’s Trade Name Review Questioned At Public Meeting

Industry wonders whether its pilot submissions hold weight against agency evaluations.

Related Content

Topics

UsernamePublicRestriction

Register

PS067816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel